Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products
DEA proposes to revoke the exemption status for inactive butalbital products, reclassifying them as controlled substances subject to full DEA regulations.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Pharmacies, wholesalers, and practitioners that handle or dispense inactive butalbital products currently listed on DEA's Table of Exempted Prescription Products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt; proposed rule comment period and effective date to be determined.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Inactive butalbital products would lose their exempted status and become controlled substances (likely Schedule III or IV), requiring DEA registration, recordkeeping, security, and reporting compliance.
Who it affects
Pharmacies, wholesalers, and practitioners that handle or dispense inactive butalbital products currently listed on DEA's Table of Exempted Prescription Products.
What you must do
Identify any inactive butalbital products in inventory or supply chain; prepare to obtain or amend DEA registration to handle controlled substances; implement controlled substance recordkeeping, security, and reporting procedures.
Deadline
Not specified in the excerpt; proposed rule comment period and effective date to be determined.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- New Maine law increases access to birth control at pharmacies - WGME
- Andrew Jonathan Morgan: Final Debarment Order
- SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
- Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments
- Schedules of Controlled Substances: Rescheduling of Marijuana; Withdrawal